127294-70-6 Balofloxacin AKSci G572
 
 
Loading Please Wait...
  G572    AKSci Bulk Reagent
Balofloxacin, 98% (HPLC)
 
Baloxin
IDENTITY
CAS Number:127294-70-6
MDL Number:MFCD00864925
MF:C20H24FN3O4
MW:389.42
BRN:8362117
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:98% (HPLC)
Physical Form (at 20°C):Solid
Melting Point:131-137°C
Long-Term Storage:Store long-term at 2-8°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

REVIEW
 Balofloxacin, an orally active fluoroquinolone antibiotic, has been developed by Choongwae Pharma in Korea for the treatment of urinary tract infection. It functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase IV, which is an enzyme necessary to separate replicated DNA, thereby inhibiting cell division.

REFERENCES
[1]Nagano, Hiroyuki; Yokota, Takeshi; Katoh, Preparation and testing of 1-cyclopropyl-7-[(3-aminoalkyl)-3-piperidinyl]-4-quinolone-3-carboxylic acids as antibacterials Eur. Pat. Appl. (1989), EP 342675 A2 19891123.
[2] Ochi, Kiyoshige; Shimizu, Hirohito Preparation of 6-fluoro-7-(heterocyclic amino)-3-quinolonecarboxylic acid derivatives as intermediates for antibacterial agents PCT Int. Appl. (1993), WO 9302055 A1 19930204.
[3] Nakashima, Mitsuyoshi; Kosuge, Kazuhiro; Umemura, Kazuo; Takiguchi, Yoshiharu; Kondo, Kazunao; Mizuno, Atsuhiro; Uematsu, Toshihiko; Watanabe, Yuuji Clinical pharmacology of antimicrobial pylidonecarboxylic acids. III. Comparative study of newly developed compounds on pharmacokinetics in healthy humans Nippon Kagaku Ryoho Gakkai Zasshi (1995), 43(6), 647-54.
[4] Iwasaki, Hiroaki; Miyazaki, Shuichi; Tsuji, Akiyoshi; Kaneko, Yasuko; Yamaguchi, Keizo; Goto, Sachiko In vitro and in vivo antibacterial activities of balofloxacin, a novel fluoroquinolone Nippon Kagaku Ryoho Gakkai Zasshi (1995), 43(Suppl. 5), 17-26.
[5] Sakamoto, Mitsuo; Nakazawa, Yasushi; Shindo, Nahoko; Maezawa, Hiromi; Yoshikawa, Kohji; Yoshida, Masaki; Shiba, Kohya; Sakai, Osamu; Saito, Atsushi Basic and clinical studies of balofloxacin Nippon Kagaku Ryoho Gakkai Zasshi (1995), 43(Suppl. 5), 206-15.
[6] Kawahara S, Tada A, Nagare H. In vitro antimycobacterial activities of a new quinolone, balofloxacin]. Kekkaku. 2001 Jan;76(1):29-31.
[7] Alksne, L. Balofloxacin Choongwae. Curr Opin Investig Drugs 2003, 4 (2): 224-9.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501

Current as of April 19, 2024


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.


CATEGORIES
 APIs and Bioactives > Antibacterials, Quinolones


PubChem
  @PubMed